louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00657436: Myeloid-Related Protein in Evaluation of Acute Chest Pain in the Emergency Departement
Official title: Study of Myeloid-related Protein 8/14 and Additional Biomarkers (Multi Marker Approach) for Early Diagnosis and Risk Stratification in Patients Presenting With Acute Chest Pain at the Emergency Department
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myocardial Ischemia
Acute Coronary Syndrome
Myocardial Infarction
Coronary Occlusion
Coronary Thrombosis
Keywords: Acute Coronary Syndrome
Myocardial Infarction
Coronary Artery Disease
Lead sponsor: University of Zurich
Sponsor class: OTHER
Collaborators: name: Swiss National Science Foundation
First posted: 2008-04-14
Enrollment: 403
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Consecutive patients - systematic sampling - presenting with acute chest pain at the emergency room in which determination of cardiac biomarkers is indicated for clinical diagnostics

Brief summary: The purpose of the study is the evaluation of multiple biomarkers related to acute coronary syndromes, including myeloid-related protein 8/14 (MRP 8/14), along with established clinical markers, for early diagnosis and risk stratification in patients presenting with acute chest pain at the emergency department.

Study hypothesis: MRP 8/14, alone or together with other established or new biomarkers, increases the earliness, sensitivity, and specificity of diagnosing acute coronary syndromes.


Eligibility criteria: Inclusion Criteria:

* All patients in the emergency department of the University Hospital Zurich with measurement of troponin during the routine diagnostic evaluation.

Exclusion Criteria:

* Refusal or inability to give informed consent.

Primary outcomes:
measure: Diagnosis of acute coronary syndrome
timeFrame: Emergency room and/or hospital stay
Secondary outcomes:
measure: Incidence of any acute coronary event
timeFrame: 1 year
measure: Morbidity from coronary artery disease
timeFrame: 1 year
measure: Mortality
timeFrame: 1 year
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: Cardiology, University Hospital
Study officials:
affiliation: Cardiology, University Hospital Zurich
name: Willibald Maier, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Altwegg LA, Neidhart M, Hersberger M, Muller S, Eberli FR, Corti R, Roffi M, Sutsch G, Gay S, von Eckardstein A, Wischnewsky MB, Luscher TF, Maier W. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J. 2007 Apr;28(8):941-8. doi: 10.1093/eurheartj/ehm078. Epub 2007 Mar 26.
Clinical trial NCT01742936: Point of Care Testing in Pediatric Patients Undergoing Major Surgery
Official title: Point of Care Testing for Coagulation Function Versus Standard Laboratory Testing in Pediatric Patients Undergoing Major Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Spinal Fusion
Cardiopulmonary Bypass
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2012-12-06
Enrollment: 100
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The current study proposes to investigate Point of Care Testing (POCT) (Coagcheck®) and compare obtained results versus standard laboratory coagulation parameters prothrombin time (PT) and partial thromboplastin time (PTT). The time difference in obtaining the two results will also be examined. A total of 100 pediatric patients undergoing spinal surgery or cardiopulmonary bypass will be enrolled and consented per protocol. Blood samples will be obtained simultaneously tested on both the standard laboratory apparatus and the Coagcheck® device. If the two results are comparable, this could have immediate clinical application and impact in the operating room as POCT results are available within 2-3 minutes compared to 1-2 hours for standard laboratory samples.


Eligibility criteria: Inclusion Criteria:

* Undergoing elective posterior spinal fusion surgery at Nationwide Children's Hospital
* Parents willing \& able to provide informed consent
* Child able to provide assent (if age appropriate)

Exclusion Criteria:

* Pre-existing bleeding disorders
* Any other circumstance which, in the opinion of the investigator, would put the patient at increased risk.

Primary outcomes:
measure: International Normalized Ratio (INR) on CoaguChek
timeFrame: At end of surgery (an average of 2-4 hrs for cardiac bypass and 4-6 hrs. for spinal fusion)
measure: International Normalized Ratio (INR) Performed by Hospital Laboratory
timeFrame: At end of surgery (an average of 2-4 hrs for cardiac bypass and 4-6 hrs. for spinal fusion)
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
References:
Clinical trial NCT06097936: New Prognostic and Predictive Biomarkers for HPV-associated Oropharyngeal Cancer
Official title: New Prognostic and Predictive Biomarkers for HPV-associated Oropharyngeal Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: PREDICTIVE BIOMARKERS
Evaluation of HPV-specific E5 Transcript Expression in a Cohort of Patients With HPV-associated OPC
HPV 16 Positive Oropharyngeal Tumors (OPC)
Keywords: HPV 16
oropharyngeal tumors (OPC)
Lead sponsor: Regina Elena Cancer Institute
Sponsor class: OTHER
Collaborators: name: University of California, San Diego
name: Lega Italiana per la Lotta contro i Tumori
First posted: 2023-10-24
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: The control group will be enlisted from among the subjects referred to the IRE outpatient clinic and/or the outpatient clinics of the LILT Provincial Committees collaborating with the Project to undergo a screening/checkup visit.

Samples will be collected in a mouthwash (i.e., Listerine) and stored in suitable solution to preserve nucleic acids (i.e., PreservCyt Transport Medium) and sent by courier from the peripheral centers to the IFOs where they will be appropriately analyzed.

Brief summary: The study involves the coexistence of a retrospective part, in which a group of patients with HPV-associated OPC for whom follow-up data of at least 2 years after diagnosis are available, designed in order to evaluate the expression of HPV16-specific E5 transcript as well as that of pEGFR and HLA, and a multicenter prospective part, involving the enrollment of a control group, enrolled at the ENT outpatient clinic of the IRE and the outpatient clinics of the relevant LILT provincial committees, to better elucidate the role of HPV16-E5 in identifying potentially transforming infections due to the presence of HPV.


Eligibility criteria: Inclusion Criteria:

* Male subjects
* age \> 18 years
* current and/or former smokers
* reporting at least 5 (Souza 2017) lifetime oral sex partners
* Written informed consent

Exclusion Criteria:

* Oral pathology
* inability to understand and sign an informed consent form

Primary outcomes:
measure: Presence of specific mRNA for the E5 oncoprotein in HPV-associated OPC samples
timeFrame: Sample collection period: 6 months Total duration of the study: 12 months
Secondary outcomes:
measure: Presence of specific mRNA for the E5 oncoprotein in HPV-associated OPC samples
timeFrame: Sample collection period: 6 months Total duration of the study: 12 months
Other outcomes:
Locations:
city: Rome
country: Italy
facility: "Regina Elena" National Cancer Institute
Study officials:
References:
Clinical trial NCT05733936: Biomechanical Determinants of Different Rehabilitation Protocols for ACL Reconstruction
Official title: Assessment of Biomechanical Determinants of Rehabilitation Protocols for ACL Reconstruction on the Quality of Performance and Risk of Reinjury: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Knee Injuries
Rehabilitation
Lead sponsor: Delta University for Science and Technology
Sponsor class: OTHER
First posted: 2023-02-17
Enrollment: 105
Sex: MALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Purpose of the study is to investigate the effects of the criterion rehabilitation protocol versus accelerated rehabilitation protocol on the biomechanical determinants of the quality of performance and risk of reinjury.


Eligibility criteria: Inclusion Criteria:

* Amateur male athletes who underwent ACLR surgery with an autologous hamstring (HS) graft.
* Ranging in age from 18 to 35 years.
* Underwent a pre-operative rehabilitation program with minimal knee effusion, full Extension, good patellofemoral mobility
* Ability to actively control the quadriceps.

Exclusion Criteria:

* ACLR with any graft other than a hamstring graft
* ACL revision surgery
* associated medial or lateral ligamentous injuries
* previous meniscectomy or meniscal repair
* simultaneous meniscectomy or meniscus repair with the ACLR
* cartilage damage.

Primary outcomes:
measure: Dynamic knee valgus during Single leg landing-jump test using CLINICAL CLIMA 3DMA
timeFrame: 15 minutes
measure: Lateral trunk flexion during Single leg landing-jump test using CLINICAL CLIMA 3DMA
timeFrame: 15 minutes
measure: knee flexion angle during Single leg landing-jump test using CLINICAL CLIMA 3DMA
timeFrame: 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Gamasa
country: Egypt
facility: Delta university
state: Eldakahlyia
Study officials:
References:
Clinical trial NCT00338936: Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)
Official title: A 52-week Extension to the Factorial Study to Evaluate the Efficacy and Safety of VAH631 (Valsartan and Hydrochlorothiazide Combined) and Alone in Essential Hypertensive Patients - Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) -
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hypertension
Keywords: Hypertension
Valsartan
Hydrochlorothiazide
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2006-06-20
Enrollment: 362
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is designed to provide long-term safety and efficacy data for the combination doses of VAH (VAL/ HCTZ) 40/6.25mg and 80/12.5mg in essential hypertensive patients. The 350 patients (approximately) who have successfully finished the core trial CVAH631B1303 and signed consent for the extension will be enrolled into this study.


Eligibility criteria: Inclusion Criteria:

* Patients who successfully complete the core study (Protocol 1303)
* Outpatients

Exclusion Criteria:

* Presence of crucial protocol violation in Protocol 1303
* Patients who experienced any adverse events considered serious and drug related in Protocol 1303.

Primary outcomes:
measure: Assessment of safety through reporting of adverse events, serious adverse events and deaths over 52 weeks.
Secondary outcomes:
measure: Change from baseline in average sitting diastolic blood pressure after 52 weeks
measure: Change from baseline in average sitting systolic blood pressure after 52 weeks
measure: Change from baseline in average standing diastolic blood pressure after 52 weeks
measure: Change from baseline in average standing systolic blood pressure after 52 weeks
measure: Laboratory abnormalities after 52 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharma Ag
role: STUDY_DIRECTOR
References:
Clinical trial NCT04920136: Gain of Keratinized Mucosa Around Teeth and Dental Implants Using a Combination of Strip Gingival Graft and Acellular Dermal Matrix
Official title: Gain of Keratinized Mucosa Around Teeth and Dental Implants Using a Combination of Strip Gingival Graft and Acellular Dermal Matrix
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Gingival Recession
Lack of Keratinized Attached Peri-implant Mucosa
Thin Gingiva
Keywords: Attached mucosa
Keratinized tissue
Dental implants
Connective tissue
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2021-06-09
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to compare the two techniques to achieve change in the tissue quality at areas of lack of Keratinized Tissue (KT) using soft tissue grafting with autogenous graft material (Free Gingival Graft)(FGG) vs Strip gingival graft with acellular dermal matrix (ADM) (SGG+ADM).

Detailed description: This investigation is a randomized controlled trial of two techniques to achieve change in the tissue quality at areas of lack of Keratinized Tissue (KT) using soft tissue grafting with autogenous graft material (Free Gingival Graft)(FGG) vs Strip gingival graft with acellular dermal matrix (ADM) (SGG+ADM). To evaluate to determine if either grafting technique (FGG vs SGG+ADM) demonstrates superiority in clinical (amount of KT increase, tissue thickness increase, and practitioner-assessed esthetics) and patient-centered outcomes (pain, swelling, change in daily activities, and patient-assessed esthetics) in a controlled study.

Eligibility criteria: Inclusion Criteria:

* English speaking
* At least 18 years old
* Able to read and understand informed consent document
* Patients with teeth/implants lacking keratinized tissue.
* Must be a patient of the UAB Dental School
* Presence of periodontally healthy, non-carious neighboring teeth, healthy implants or edentulous ridges on either side of the involved site(s)

Exclusion Criteria:

* Non-English speaking
* Less than 18 years old
* Smokers/tobacco users (\>10 cigarettes/day)
* Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing
* Presence of active periodontal disease
* Previous soft tissue grafting at the site(s) to be treated

Primary outcomes:
measure: Quality of soft tissue regenerated
timeFrame: From baseline to 12 months
measure: Quantity of soft tissue regenerated (Width of Keratinized Tissue)
timeFrame: From baseline to 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Unversity of Alabama at Birmingham, School of Dentistry
state: Alabama
Study officials:
References:
Clinical trial NCT01069536: Efficacy and Akathisia Incidence of Slow Infusion Metoclopramide
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Akathisia
Nausea
Keywords: metoclopramide
akathisia
nausea
vomiting
antiemetic
improvement of nausea
Lead sponsor: Pamukkale University
Sponsor class: OTHER
First posted: 2010-02-17
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Study Objective:

The purpose of this study is to compare the effects of metoclopramide administration in bolus versus slow infusion medications in ED patients complaining of nausea for the determination of the therapeutic effect and prevention of akathisia.

Methods:

This was a prospective, randomized, double-blind trial. The investigation was held between 01 March 2007 and 01 May 2008, in the Emergency Department of Pamukkale University Faculty of Medicine. The patients with moderate to severe nausea randomized and divided into two groups as for the previously planned administration type of drug. Ten mg metoclopramide was administered in one group with slow infusion (SIG) in 15 minutes, via 2 minutes bolus infusion (BIG) into the other group. Whole procedure was observed, akathisia and nausea scores and vital changes were recorded.


Eligibility criteria: Inclusion Criteria:

* Patients 18 through 65 years of age and 50-90 kg of weight who presented to the ED with primary or secondary complaints of moderate to severe nausea who not use of commonly accepted antiemetic within the previous 24 hours were eligible for this study.
* Their peripheral oxygen saturation level was 90% or over while respirating room air and free of any respiratory problems.

Exclusion Criteria:

* Patients with mild symptoms of nausea
* Altered mental status
* Abnormal vital signs
* Any known allergy to the metoclopramide
* Previously enrolled in the study
* Known renal failure or insufficiency
* GIS hemorrhage, ileus and/or perforation
* Women who were pregnant and lactating
* Those with a history of epilepsy
* Admitted to the ED due to acute psychiatric symptoms
* Restless legs syndrome
* Parkinson
* Organic brain disease
* Phaeochromocytoma
* Patient with alcohol
* Anticholinergic, sedative, hypnotic, trankilizan, digoxin, cimetidine, tetracycline and levo-dopa use
* Presence of severe agitation akathisia can not be evaluated and uncooperative individuals.

Primary outcomes:
measure: akathisia and nausea scores
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03110536: The Burnout Syndrome in Emergency Department Triage Nurses
Official title: Sindromul de Burnout la asistenții Medicali de Triaj Din unitățile de Primire urgențe
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Burnout, Professional
Nurse's Role
Keywords: Burnout syndrome
Triage
Nurse
Emergency Department
Romania
Lead sponsor: Iuliu Hatieganu University of Medicine and Pharmacy
Sponsor class: OTHER
Collaborators: name: County Clinical Emergency Hospital Cluj-Napoca
First posted: 2017-04-12
Enrollment: 56
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Emergency Department nurses from Emergency Clinical County Hospital Cluj and Emergency Clinic Hospital for Children Cluj-Napoca.

Brief summary: Assessment of burnout syndrome of triage nurses from Emergency Departments from Cluj-Napoca, Romania.

Detailed description: This study is aiming at assessing the burnout syndrome amongst triage nurses working in the Emergency Departments in Cluj-Napoca. The study design is observational, prospective and multicentric.

At this moment, there are 43 nurses covering triage shifts in the Emergency Clincial County Hospital Cluj and 18 more within Emergency Clinical Hospital for Children Cluj-Napoca. On average, these ED roughly attend 90.000 patients yearly.

Questionnaires are based on Copenhagen Burnout Inventory, with additional clinical cases that require triage coding according to The Romanian National Triage Protocol of 2016. Each triage nurse will complete the questionnaire when beginning the triage shift and after a period of 2, 4 or 6 hours.

Eligibility criteria: Inclusion Criteria:

* ED nurse within Emergency Clinical County Hospital Cluj and Emergency Clinic Hospital for Children Cluj-Napoca.

Exclusion Criteria:

* triage experience of at least 1 year

Primary outcomes:
measure: Assessment of burnout syndrome in triage ED nurses
timeFrame: 2 to 6 hours
Secondary outcomes:
measure: Efficacy of triage ED nurses
timeFrame: 2 to 6 hours
Other outcomes:
Locations:
city: Cluj-Napoca
country: Romania
facility: Emergency County Hospital for Children
state: Cluj
city: Cluj-Napoca
country: Romania
facility: Emergency Clinical County Hospital Cluj-Napoca - Emergency Department
state: Cluj
Study officials:
References:
Clinical trial NCT04189536: An SMS Intervention to Improve Adherence to Stimulant Medications in Adults With ADHD
Official title: An SMS Intervention to Improve Adherence to Stimulant Medications in Adults With ADHD
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Attention Deficit/Hyperactivity Disorder
Keywords: Attention Deficit/Hyperactivity Disorder
ADHD
SMS Intervention
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Shire
First posted: 2019-12-06
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study will assess the efficacy of the text messaging (SMS-based) disease management intervention to improve adherence to stimulants in adults with Attention Deficit/Hyperactivity Disorder (ADHD).

Participants in the study will receive customized text messages twice a day, every day, for a duration of 9 months. The text messages will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.


Eligibility criteria: Inclusion Criteria:

* Male and female adults 18 to 55 years
* A diagnosis of Diagnostic and Statistical Manual Diploma in Social Medicine (DSM-V) Attention Deficit Hyperactivity Disorder based on clinical assessment
* Is starting stimulant medication or has begun treatment with stimulant medication within six months of study enrollment
* Proficient in English
* Has a cellular phone with text messaging capabilities and is interested in and willing to receive text messages

Exclusion Criteria:

* Serious chronic medical or psychiatric condition that, in the investigator's opinion, puts the subject at risk for taking a stimulant
* Pregnant or nursing females
* Investigator and his/her immediate family
* Unwilling/unable to comply with study procedures

Primary outcomes:
measure: Adherence to Stimulants
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Joseph Biederman, MD
role: PRINCIPAL_INVESTIGATOR
References: